Geron Licenses MaxCyte Cell Loading Technology for Use in Closed-System Cancer Vaccine Manufacturing
MaxCyte, Inc. and Geron Corporation (Nasdaq:GERN) announced today a license, option, development, and supply agreement to utilize MaxCyte’s proprietary cell loading system in the manufacture of mRNA-loaded dendritic cell-based vaccines, including Geron’s GRNVAC1 telomerase vaccine.
Thermogenesis Gets Health Canada Regulatory License to Market AutoXpress System
The specific regulations allows GE Healthcare, the AXP system distributor, to begin its sales and marketing effort to cord blood banks and hospitals in Canada.
Introgen Therapeutics, Inc. (INGN) Awarded Patent For Gene-Based Therapies Combined With Conventional Therapies
Introgen Therapeutics, Inc. announced today that a patent has been awarded by the U.S. Patent and Trademark Office which covers, for example, administration of chemotherapeutic drugs, radiation therapies, or other agents that have a damaging effect on the DNA of cancer cells, to a cancer patient, followed by administration of a desired therapeutic gene, such as one or more of Introgen’s molecular therapies.
Genentech Submits Supplemental Biologics License Application for Adjuvant Herceptin in Early-Stage HER2-Positive Breast Cancer
Genentech, Inc. (NYSE: DNA) announced today that the company completed the submission of a supplemental Biologics License Application (sBLA) with the U.S. Food and Drug Administration (FDA) for use of Herceptin® (Trastuzumab) to treat early-stage, HER2-positive breast cancer.
India’s Reliance Life to Launch Stem Cell Therapies Soon
Reliance Life Sciences (RLS), the pioneer of embryonic stem cell research in the country, is likely to launch its first stem cell-based therapies for neuro-degenerated diseases, including Parkinson’s and ocular diseases and spinal cord injury soon.
LCT Reports Positive Meetings with FDA and MedSafe – Preparing for Cell Therapy Trials
Living Cell Technologies Limited (ASX:LCT) today reported it has held positive meetings with the US Food and Drug Administration (FDA) and New Zealand’s MedSafe, regarding its NeurotrophinCell and DiabeCell products.
Stem Cell Innovations Formerly Interferon Sciences (IFSC.PK) And Amphioxus Cell Technologies Announce Merger And Related Events
Stem Cell Innovations, Inc. (IFSC.OB), formerly known as Interferon Sciences, Inc., and Amphioxus Cell Technologies, Inc., a privately held company, today announced the merger of the two companies, a new management team, the completion of an approximately $3.8 million private placement, and certain debt exchanges.
GenVec Names Russell Wesdyk Vice President of Business Development and Strategic Planning
GenVec, Inc.(Nasdaq:GNVC) announced today that Russell P. Wesdyk has joined the company as vice president of business development and strategic planning, a new position reporting to company president and chief executive officer Paul Fischer, Ph.D.